AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CervoMed: Boral Capital Raises Buy Rating to $15 from $10 PT
ByAinvest
Monday, Aug 11, 2025 7:18 am ET1min read
CervoMed: Boral Capital Raises Buy Rating to $15 from $10 PT
CervoMed Inc. (NASDAQ:CRVO) has seen a significant upgrade in its stock rating from Boral Capital, which has increased its price target for the biotechnology company. Boral Capital has raised its rating from a "buy" to a "moderate buy" and has revised its price target from $10.00 to $15.00 per share [1].This upgrade comes amidst a period of increased analyst interest in CervoMed, with multiple brokerages updating their coverage on the stock. Chardan Capital, for instance, increased its price target from $14.00 to $15.00 and maintained a "buy" rating [1]. Canaccord Genuity Group also raised its price target from $21.00 to $27.00, reiterating its "buy" rating [1].
Institutional investors have been actively participating in CervoMed's stock as well. Rhumbline Advisers increased its stake in the company by 35.5% in the first quarter, while other institutional investors like HighTower Advisors LLC, Bank of New York Mellon Corp, DRW Securities LLC, and Mariner LLC have also initiated new positions in the stock [1].
Despite the positive analyst sentiment, CervoMed's stock has faced some challenges. The company reported a loss of $0.70 per share in the second quarter of 2025, missing analyst estimates by 19% [2]. However, the company's revenue exceeded estimates by 22%, suggesting that while earnings have been a concern, revenue growth remains a positive indicator.
Looking ahead, CervoMed's revenue is forecast to grow at an average annual rate of 11% over the next three years, which is slightly lower than the 19% growth forecast for the US biotech industry as a whole [2]. This growth trajectory, along with the recent analyst upgrades, could provide support for CervoMed's stock price in the coming months.
References:
[1] https://www.marketbeat.com/instant-alerts/cervomed-inc-nasdaqcrvo-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2025-08-04/
[2] https://finance.yahoo.com/news/cervomed-second-quarter-2025-earnings-143546613.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet